Published in Pharm Res on June 07, 2017
Ascending Single Doses of AMG 334 in Healthy Subjects and Migraine Patients | NCT01688739
Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache (2001) 6.93
Migraine prevalence, disease burden, and the need for preventive therapy. Neurology (2007) 6.57
Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA (1992) 4.77
Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci (2004) 4.28
Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther (2008) 4.17
General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn (2001) 3.21
Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet (2010) 2.20
Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn (2008) 1.97
Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther (1994) 1.64
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol (2016) 1.58
Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J (2009) 1.48
The epidemiology of primary headache disorders. Semin Neurol (2010) 1.36
Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor. J Pharmacol Exp Ther (2015) 0.98
Theoretical considerations of target-mediated drug disposition models: simplifications and approximations. Pharm Res (2011) 0.97
Reproducibility of the capsaicin-induced dermal blood flow response as assessed by laser Doppler perfusion imaging. Br J Clin Pharmacol (2007) 0.96
In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232. J Pharmacol Exp Ther (2013) 0.90
Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974). Br J Clin Pharmacol (2010) 0.88
Calcitonin gene-related peptide8-37 antagonizes capsaicin-induced vasodilation in the skin: evaluation of a human in vivo pharmacodynamic model. J Pharmacol Exp Ther (2008) 0.86
Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist. Br J Clin Pharmacol (2015) 0.81
Translational Pharmacodynamics of Calcitonin Gene-Related Peptide Monoclonal Antibody LY2951742 in a Capsaicin-Induced Dermal Blood Flow Model. J Pharmacol Exp Ther (2015) 0.80
Development of anti-migraine therapeutics using the capsaicin-induced dermal blood flow model. Br J Clin Pharmacol (2015) 0.79